Hypertensive disorders of pregnancy are among the leading contributors to maternal mortality worldwide, but up to 60% of hypertension-related maternal deaths are potentially preventable.
Hypertensive disorders of pregnancy are among the leading contributors to maternal mortality worldwide. Approximately 30,000 deaths annually are attributed to hypertensive disorders including preeclampsia, eclampsia, and HELLP syndrome.1,2 In the United States, hypertension-related disorders account for approximately 7.4% of the almost 800 pregnancy-related deaths that occur each year.3 Women with preeclampsia/eclampsia are at 3 to 25 times the risk of severe pregnancy complications including placental abruption, disseminated intravascular coagulation (DIC), renal failure, pulmonary edema and aspiration pneumonia.4,5 Recent reviews suggest that up to 60% of hypertension-related maternal deaths are potentially preventable-there continue to be missed opportunities for appropriate, recommended care of severe maternal hypertension.6For more information: Hypertensive disorders of pregnancyÂ
1. Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013;25(2):124-132.2. Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, et al. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):980-1004.3. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-Related Mortality in the United States, 2011-2013. Obstet Gynecol. 2017;130(2):366-373.4. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy. 2003;22(2):203-212.5. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. 2012;36(1):56-59.6. Main EK, McCain CL, Morton CH, Holtby S, Lawton ES. Pregnancy-related mortality in California: causes, characteristics, and improvement opportunities. Obstet Gynecol. 2015;125(4):938-947.
Fasting glucose at GDM diagnosis may predict postpartum glucose abnormalities
February 6th 2025A recent study suggests that elevated fasting glucose levels at the time of gestational diabetes diagnosis could be an early indicator of postpartum glucose intolerance, emphasizing the need for close monitoring after delivery.
Read More
Ulipristal plus misoprostol shows promise for medication abortion
February 5th 2025A recent study found that ulipristal acetate followed by misoprostol is a safe, effective, and acceptable option for medication abortion, offering a potential alternative in areas with limited access to mifepristone.
Read More
Identification and management of patients at increased risk for breast cancer
February 5th 2025With breast cancer being the most diagnosed invasive cancer in the United States, OB-GYN practitioners play a crucial role in identifying high-risk patients and guiding them through screening, prevention, and risk-reduction strategies.
Read More
Fasting glucose at GDM diagnosis may predict postpartum glucose abnormalities
February 6th 2025A recent study suggests that elevated fasting glucose levels at the time of gestational diabetes diagnosis could be an early indicator of postpartum glucose intolerance, emphasizing the need for close monitoring after delivery.
Read More
Ulipristal plus misoprostol shows promise for medication abortion
February 5th 2025A recent study found that ulipristal acetate followed by misoprostol is a safe, effective, and acceptable option for medication abortion, offering a potential alternative in areas with limited access to mifepristone.
Read More
Identification and management of patients at increased risk for breast cancer
February 5th 2025With breast cancer being the most diagnosed invasive cancer in the United States, OB-GYN practitioners play a crucial role in identifying high-risk patients and guiding them through screening, prevention, and risk-reduction strategies.
Read More
2 Commerce Drive
Cranbury, NJ 08512